Evidence map›Paper›PMID 34769072›Full record

ArticleInternational journal of molecular sciences2021

Establishment of a Rapid Detection System for ISG20-Dependent SARS-CoV-2 Subreplicon RNA Degradation Induced by Interferon-α.

Yutaka Furutani, Mariko Toguchi, Shoko Higuchi, Kaori Yanaka, Luc Gailhouste, Xian-Yang Qin, Takahiro Masaki, Sae Ochi, Tomokazu Matsuura

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. The Rayleigh Quotient and Contrastive Principal Component Analysis II.bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yutaka FurutaniRIKEN Cluster for Pioneering Research Liver Cancer Prevention Research Unit, Saitama 351-0198, Japan.ORCID 0000-0002-2945-0166
Mariko ToguchiRIKEN Cluster for Pioneering Research Liver Cancer Prevention Research Unit, Saitama 351-0198, Japan.
Shoko HiguchiRIKEN Cluster for Pioneering Research Liver Cancer Prevention Research Unit, Saitama 351-0198, Japan.
Kaori YanakaRIKEN Cluster for Pioneering Research Liver Cancer Prevention Research Unit, Saitama 351-0198, Japan.
Luc GailhousteRIKEN Cluster for Pioneering Research Liver Cancer Prevention Research Unit, Saitama 351-0198, Japan.
Xian-Yang QinRIKEN Cluster for Pioneering Research Liver Cancer Prevention Research Unit, Saitama 351-0198, Japan.ORCID 0000-0002-0110-6849
Takahiro MasakiDepartment of Laboratory Medicine, The Jikei University School of Medicine, Tokyo 105-8461, Japan.ORCID 0000-0001-9857-3453
Sae OchiDepartment of Laboratory Medicine, The Jikei University School of Medicine, Tokyo 105-8461, Japan.ORCID 0000-0003-4133-3170
Tomokazu MatsuuraRIKEN Cluster for Pioneering Research Liver Cancer Prevention Research Unit, Saitama 351-0198, Japan.ORCID 0000-0002-7963-3518
Jikei University School of Medicine · JPPioneer (Japan) · JP

Funding

Japan Agency for Medical Research and Development JP21fk0310112Jikei University School of Medicine
6 · The paper itself

Abstract

Inhaled nebulized interferon (IFN)-α and IFN-β have been shown to be effective in the management of coronavirus disease 2019 (COVID-19). We aimed to construct a virus-free rapid detection system for high-throughput screening of IFN-like compounds that induce viral RNA degradation and suppress the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We prepared a SARS-CoV-2 subreplicon RNA expression vector which contained the SARS-CoV-2 5'-UTR, the partial sequence of ORF1a, luciferase, nucleocapsid, ORF10, and 3'-UTR under the control of the cytomegalovirus promoter. The expression vector was transfected into Calu-3 cells and treated with IFN-α and the IFNAR2 agonist CDM-3008 (RO8191) for 3 days. SARS-CoV-2 subreplicon RNA degradation was subsequently evaluated based on luciferase levels. IFN-α and CDM-3008 suppressed SARS-CoV-2 subreplicon RNA in a dose-dependent manner, with IC50 values of 193 IU/mL and 2.54 μM, respectively. HeLa cells stably expressing SARS-CoV-2 subreplicon RNA were prepared and treated with the IFN-α and pan-JAK inhibitor Pyridone 6 or siRNA-targeting ISG20. IFN-α activity was canceled with Pyridone 6. The knockdown of ISG20 partially canceled IFN-α activity. Collectively, we constructed a virus-free rapid detection system to measure SARS-CoV-2 RNA suppression. Our data suggest that the SARS-CoV-2 subreplicon RNA was degraded by IFN-α-induced ISG20 exonuclease activity.

Indexed as

Antiviral AgentsCell Line, TumorDose-Response Relationship, DrugDrug Evaluation, PreclinicalExoribonucleasesGenetic VectorsHeLa CellsHumansInterferon-alphaLuciferasesNaphthyridinesOxadiazolesRepliconRNA, ViralSARS-CoV-2Antiviral AgentsCDM-3008ExoribonucleasesInterferon-alphaISG20 protein, humanLuciferasesNaphthyridinesOxadiazolesRNA, ViralCDM-3008COVID-19interferoninterferon-stimulated genesISG20replicon

Identifiers

PMID34769072
PMCPMC8583800
OpenAlexW3208767947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.